A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis

Dokumente

  • Coe_Cossington_Collett_Soundy_Izadi_Ovington_Durkin_Kirsten_RCT_feasability_trial_flavonoid-rich_cocoa

    846 KB, PDF-Dokument

  • Shelly Coe
  • Jo Cossington
  • Johnny Collett
  • Andrew Soundy
  • Hooshang Izadi
  • Martin Ovington
  • Luke Durkin
  • Maja Kirsten
  • Miriam Clegg
  • Ana Cavey
  • Derick T Wade
  • Jacqueline Palace
  • Gabriele C DeLuca
  • Kim Chapman
  • Jane-Marie Harrison
  • Elizabeth Buckingham
  • Helen Dawes

Abstract

The impact of flavonoids on fatigue has not been investigated in relapsing and remitting multiple sclerosis (RRMS).

OBJECTIVE: To determine the feasibility and estimate the potential effect of flavonoid-rich cocoa on fatigue and fatigability in RRMS.

METHODS: A randomised double-blind placebo-controlled feasibility study in people recently diagnosed with RRMS and fatigue, throughout the Thames Valley, UK (ISRCTN: 69897291). During a 6-week intervention participants consumed a high or low flavonoid cocoa beverage daily. Fatigue and fatigability were measured at three visits (weeks 0, 3 and 6). Feasibility and fidelity were assessed through recruitment and retention, adherence and a process evaluation.

RESULTS: 40 people with multiple sclerosis (10 men, 30 women, age 44±10 years) were randomised and allocated to high (n=19) or low (n=21) flavonoid groups and included in analysis. Missing data were <20% and adherence to intervention of allocated individuals was >75%. There was a small effect on fatigue (Neuro-QoL: effect size (ES) 0.04, 95% CI -0.40 to 0.48) and a moderate effect on fatigability (6 min walk test: ES 0.45, 95% CI -0.18 to 1.07). There were seven adverse events (four control, three intervention), only one of which was possibly related and it was resolved.

CONCLUSION: A flavonoid beverage demonstrates the potential to improve fatigue and fatigability in RRMS.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0022-3050
DOIs
StatusVeröffentlicht - 05.2019
Extern publiziertJa
PubMed 30833449